Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Amneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past week

Amneal to Report First Quarter 2024 Results on May 3, 2024

Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

Amneal Pharmaceuticals Inc (AMRX) Reports Mixed 2023 Financial Results

Amneal Reports Fourth Quarter and Full Year 2023 Financial Results

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

Insiders the biggest winners as Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) market cap rises to US$1.8b

Amneal to Participate at Upcoming Investor Conference

Amneal Announces Complete Response Resubmission for IPX203 New Drug Application